JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

The Triphenyl Imidazole (TPI) Scaffold as a Privileged Structure in Drug Discovery: Recent Advances in Multi-Target Kinase Inhibition and SAR Profiling.

Neha P. Sharnagate*, Adesh B. Samrit, Mahima R. Bijewar, Deepak S. Dodke, Prachi J. Dangre
Priydarshini J. L.College of pharmacy, Nagpur, Maharashtra, India -440016

Abstract:

The triaryl imidazole (TPI) scaffold has emerged as a privileged structure in modern drug discovery due to its versatile biological activity, distinct electronic profile, and structural adaptability. Characterized by an electron-rich imidazole core and three hydrophobic aryl rings, TPI derivatives demonstrate strong interactions with diverse biological targets, enabling potent inhibitory effects across multiple disease pathways. Recent developments highlight their prominence as multi-target kinase inhibitors, particularly against p38 MAPK and focal adhesion kinase (FAK), where their structural framework allows optimal binding within deep hydrophobic enzyme pockets. Alongside anticancer potential, TPI derivatives also exhibit broad pharmacological activities including anti-inflammatory, analgesic, antimicrobial, antifungal, and antioxidant effects. However, their high lipophilicity and poor aqueous solubility present significant biopharmaceutical challenges, driving research toward strategic molecular derivatization, N-1 functionalization, and modern formulation approaches to improve drug-likeness. This review consolidates recent advances in synthetic strategies, structure-activity relationships, and therapeutic applications, positioning triphenyl imidazole as a robust platform for developing next-generation multitarget therapeutics.

Keywords: Triphenyl imidazole, Privileged scaffold, Kinase inhibition, focal adhesion kinase, Multi-target therapeutics, Drug design.

I: Introduction

1.1 Historical Context and Significance of the Imidazole Heterocycle

The imidazole ring, a five-membered nitrogen-containing heterocyclic system, is widely acknowledged as a pivotal scaffold in modern medicinal chemistry. Its unique structure, characterized by two nitrogen atoms, endows it with desirable electronic features, including amphoteric behavior, the capacity for tautomerism, and strong potential for hydrogen bonding and interaction with various biomolecules.[1] This adaptability has led to the inclusion of imidazole in numerous commercially available therapeutic agents targeting a vast range of diseases.[2]

Within the family of imidazole compounds, 2,4,5-triphenylimidazole (TPI), commonly known as Lophine, holds a dual significance: it is both a potent bioactive scaffold and a historical chemical curiosity. Lophine was first identified in 1877 and is recognized as one of the first known chemiluminescence (CL) compounds discovered. It emits chemiluminescence in basic solutions when oxygen is present.[3] This structural class has been consistently explored, particularly due to the favorable pharmacodynamic properties afforded by the imidazole nucleus, which shares structural similarities with the natural amino acid histidine. This similarity facilitates enhanced interaction with protein molecules and improved overall pharmacodynamic performance compared to certain other heterocycles.[4]

1.2 Chemical Properties and Biopharmaceutical Implications of 2,4,5-Triphenylimidazole (TPI)

TPI possesses the molecular formula $C_{21}H_{16}N_2$ with a molecular weight of 296.37g/mol.[5] The presence of three bulky phenyl rings (triaryl substitution) results in inherent physicochemical characteristics that are critical to its drug-like properties, both favorable and unfavorable. The compound exhibits a high melting point, typically reported in the range of 274-295 ^{0}C. A predicted pKa of 11.66 ± 0.10 is also available.[6]



Fig.(1) The Triphenyl Imidazole Scaffold

A defining feature of the TPI scaffold, directly linked to the extensive aromatic substitution, is its significant lipophilicity and resulting poor aqueous solubility. TPI is characterized as insoluble in water but readily soluble in organic solvents such as methanol.[7] This high melting point is symptomatic of strong intermolecular forces within the crystal lattice, likely arising from optimized π-π stacking interactions between the three phenyl rings, which stabilize the solid state.[8] This strong lattice energy necessitates a large input of energy for dissolution, leading directly to the observed low water solubility. In the context of the Biopharmaceutical Classification System (BCS), this combination of high lipophilicity and poor aqueous solubility suggests that TPI derivatives often fall into the challenging BCS Class II (High Permeability, Low Solubility) or even Class IV (Low Permeability, Low Solubility) categories.[9] This intrinsic lipophilicity, while advantageous for binding efficacy in hydrophobic pockets, represents the primary biopharmaceutical hurdle that must be overcome for clinical development.

The core physicochemical data for TPI are summarized below.

Table 1: Physico-Chemical Profile of 2,4,5-Triphenyl Imidazole

Property	**Value/Description**	**Source**
Molecular Formula/Weight	$C_{21}H_{16}N_2$ /296.37g/mol	5
Melting Point	274-295 ^{0}C (Literature range)	6
Water Solubility	Insoluble in water; Soluble in methanol	8
TLC Index	Rf = 0.60 (Hexane:Ethyl acetate 7:3)	5

1.3 Rationale for Review Focus: TPI as a Multi-Target Privileged Scaffold

The triaryl imidazole framework is regarded as a "privileged structure" in medicinal chemistry. The strategic placement of the electron-rich imidazole core and the three aryl substituents enables the molecule to adopt conformations suitable for binding to various enzymes, receptors, and proteins through diverse weak interactions, including hydrogen bonding, charge electrostatic interactions, and hydrophobic interactions.[10] The focus of this review is to critically analyze recent research on TPI derivatives, particularly examining the connection between structural manipulation (Synthesis and SAR). This integrated approach is essential for

identifying novel lead compounds that possess not only high therapeutic potency but also suitable pharmacokinetic profiles for eventual clinical translation.

II: Material and Method

2.1 Conventional and Established Synthesis Routes

The preparation of the TPI core is well-established, relying on multicomponent condensation reactions. The classic synthesis route involves the condensation of benzoin, benzaldehyde, and ammonia, often referred to as a Radziszewski-type synthesis. Modern variations involve the reaction of benzil and substituted benzaldehydes in equimolar quantities, yielding newer triphenyl-imidazole derivatives in good yields.[11]

During synthetic procedures, reaction progression is routinely monitored using analytical techniques such as Thin Layer Chromatography (TLC). A commonly reported Rf value for the crude product in a hexane:ethyl acetate solvent system (7:3 ratio) is 0.60. Subsequent purification and characterization rely on methods such as melting point determination, open tube capillary methods, and spectroscopic analysis (FTIR, Mass, NMR).[12]



Fig.(2) Synthetic Method of TPI

2.2 Strategic Modification for Lead Optimization

Optimization of TPI derivatives involves strategic placement of substituents to modulate biological activity and pharmacokinetic properties. The structure provides multiple sites for derivatization, with N-1 being the most chemically accessible position.

- **N-1 Functionalization:** The synthesis of 1-substituted 2,4,5-triphenyl imidazoles typically involves refluxing 2,4,5-triphenyl imidazole and an acid chloride in benzene, catalyzed by pyridine.This reaction results in N-substituted derivatives (e.g., 2-(N-substituted)-1-(2,4,5-triphenyl-1H-imidazole-1-yl) ethanone derivatives). The N-1 position is paramount for modulating properties such as polarity, metabolic stability, and achieving target specificity.[13]
- **C-2/C-4/C-5 Aryl Ring Modification:** Modifications to the three phenyl rings also profoundly influence activity. Adjustments to the core structure have been shown to enhance potential activity. For example, substituting the C-2 benzene nucleus with different functional groups has exhibited promising antifungal effects.[14]

The high potency of TPI derivatives as kinase inhibitors is highly dependent on the three aryl groups (at C-2, C-4, and C-5) occupying deep, hydrophobic binding pockets within target enzymes.[15] This structural requirement for bulky, lipophilic aryl groups is the source of the scaffold's potent efficacy. The strategic chemical manipulation at the N-1 position using simple methods like acid chloride coupling. therefore, serves as the primary mechanism for introducing polar, ionizable, or metabolically stable moieties (such as 1,2,3-triazole conjugates) necessary to improve the pharmacokinetic profile, all while preserving the critical triaryl architecture essential for maximizing binding interactions.[16]

2.3 Green Chemistry and Catalytic Approaches

Modern synthetic efforts seek to improve the efficiency and environmental profile of imidazole synthesis. Research trends highlight the use of one-pot multicomponent reactions, often catalyzed by advanced materials. Examples include the utilization of urea-functionalized Fe_3O_4/SiO_2 magnetic nanocatalysts for the synthesis of substituted imidazole derivatives. The design and characterization of $Cu/GA/Fe_3O_4@SiO_2$ nanoparticles have also been explored as catalysts for generating imidazoles.[17] These approaches increase yield, reduce waste, and represent a vital direction for sustainable pharmaceutical chemistry.

Section III: Pharmacological Spectrum

3.1 Broad Pharmacological Activities of Imidazoles

TPI derivatives are associated with a remarkable range of biological activities. The documented pharmacological effects include anti-cancer, anti-inflammatory, analgesic, anti-fungal, antibacterial, antiviral, and anti-diabetic properties.[18] This broad spectrum supports the classification of TPI as a privileged scaffold.

A promising modern development is the pursuit of single molecules capable of multi-drug treatment. This strategy is particularly relevant for complex conditions, such as inflammatory states compounded by microbial infections, where a mono-therapy offers advantages in pharmacoeconomics and patient compliance. The synthesis of 2,4,5-triphenyl-1H-imidazole-1-yl derivatives has aimed to achieve this goal, with given compound identified as the most potent derivative in one series, demonstrating dual anti-inflammatory and antimicrobial activity.[19-20]

3.2 TPI Derivatives as Critical Kinase Inhibitors

Kinase inhibition represents one of the most therapeutically significant applications of the triaryl imidazole scaffold, particularly in oncology and inflammation. The triaryl structure is ideally suited to occupying the hydrophobic and allosteric sites adjacent to the ATP-binding pocket.

3.2.1 p38 Mitogen-Activated Protein Kinase (MAPK) Inhibition

Tri- and tetra-substituted imidazole derivatives are well-known as selective inhibitors of p38MAP kinase. This enzyme is a key regulator in the inflammatory cascade, controlling the production of major pro-inflammatory cytokines such as Interleukin 1-beta (IL-1β) and Tumor Necrosis Factor alpha (TNF-α). Inhibition of p38α is a promising strategy for controlling inflammation.[21]

Mechanistically, these inhibitors often bind competitively with ATP, though they may require conformational changes for optimal affinity. Molecular docking studies have detailed the structure-activity relationships (SARs) crucial for binding potency. Key features include hydrogen bond interactions with residues in the hinge region, specifically Methionine 109(Met109) and Valine30. For example, a designed series of 1-hydroxy-2,4,5-triaryl imidazole derivatives showed inhibitory activity ranging from 28% to 82% against IL-1β release, with Compound 5g demonstrating the best action. Moreover, introducing a pyridyl C2 side chain allows the ligand to occupy the hydrophobic pocket II, a strategy that enhances inhibitory activity and selectivity.[22]

3.2.2 Focal Adhesion Kinase (FAK) Inhibition

Another significant target is Focal Adhesion Kinase (FAK). Derivatives related to TPI, such as TAE-226, function as ATP-competitive FAK inhibitors. These compounds have displayed potent anti-proliferative and anti-tumor effects in vitro and in vivo against aggressive malignancies including brain tumors and breast cancer. The potency observed for these compounds is remarkable, with IC_{50} values for active derivatives falling in the highly desirable nanomolar range (10^{-7}–10^{-8}M).

The high affinity observed in TPI derivatives is a direct consequence of the triaryl substitution pattern. The three phenyl rings confer significant bulk and π-surface area, enabling the molecule to efficiently occupy the deep, hydrophobic pockets characteristic of kinase active sites. This volume occupancy maximizes hydrophobic interactions, providing the necessary affinity that dictates the low IC_{50} values observed for FAK and p38 MAPK inhibitors.[23]

3.3 Anti-inflammatory and Analgesic Mechanisms

Beyond kinase inhibition, TPI compounds are robust anti-inflammatory and analgesic agents. Their anti-inflammatory mechanism primarily involves the inhibition of COX-1and COX-2 enzymes. This mechanism places them in the same class as non-steroidal anti-inflammatory drugs (NSAIDs). The imidazole ring is recognized as a bioisostere of the pyrazole ring, a nucleus common in many COX-2 selective inhibitors, such as Celecoxib. Therefore, TPI derivatives are structurally and mechanistically relevant to modern NSAIDs.[24]

The compounds also exhibit analgesic activity, primarily through the modification of inflammatory mechanisms and potential interaction with specific pain receptors. This analgesic property significantly enhances their therapeutic utility for managing chronic pain and inflammation-related diseases.[25]

3.4 Anticancer and Antimicrobial Activities

Imidazole derivatives constitute an important class of compounds in oncology, modulating diverse targets related to uncontrolled cell growth. These include microtubules, tyrosine and serine-threonine kinases, histone deacetylases, and poly (ADP -ribose) polymerase (PARP).A number of newly synthesized triphenyl imidazole derivatives have shown significant antiproliferative effects against various cancer cell lines, confirming their potential as lead compounds for further development.[26]

In the case of infectious diseases, imidazole derivatives are crucial as antifungal and antibacterial agents. They belong to the azole class of antifungals, which includes clinically important drugs like Miconazole and Clotrimazole. TPI derivatives have demonstrated mild to moderate activity against fungal strains like *C. albicans* and *A. niger*.[28] They generally show greater efficacy against Gram-positive bacteria compared to Gram-negative strains. The high specificity of some imidazole medications allows them to directly block microbial membranes at high doses.[29]

Conclusion

Triaryl imidazole (TPI) scaffolds demonstrate a remarkably broad and versatile pharmacological spectrum, positioning them as one of the most promising privileged structures in modern drug discovery. Their unique combination of an electron-rich imidazole core and three hydrophobic aryl rings enables strong and adaptable interactions with a wide range of biological targets. As a result, TPI derivatives exhibit potent **anticancer, anti-inflammatory, antimicrobial, antifungal, analgesic, antioxidant, and enzyme-modulating** activities. Among these, their capacity to inhibit multiple protein kinases such as p38 MAPK, FAK, and GSK-3β highlights their value in treating complex, multi-pathway diseases including cancer and chronic inflammatory disorders.

SAR analyses consistently show that the triaryl framework is central to their biological potency, while N-1 and aromatic substitutions allow fine-tuning of selectivity, polarity, and binding affinity. Despite challenges such as poor aqueous solubility and high lipophilicity, advances in molecular modification and pharmaceutical formulation continue to expand their therapeutic potential. Overall, the TPI scaffold represents a pharmacologically rich and strategically important platform for developing next-generation multi-target therapeutics, particularly in disease areas where poly-pharmacology and broad-spectrum activity are essential for effective intervention.

Reference

1. Serdaliyeva D, Nurgozhin T, Satbayeva E, Khayitova M, Seitaliyeva A, Ananyeva L. Review of pharmacological effects of imidazole derivatives. *J Clin Med Kazakhstan*. 2022;19(3):11-15.
2. Siwach A, Verma PK. Synthesis and therapeutic potential of imidazole containing compounds. *BMC Chem*. 2021;15(1):12.
3. Nakashima K. Lophine derivatives as versatile analytical tools. *Biomed Chromatogr*. 2003;17:83-95. doi:10.1002/bmc.226.
4. Zala SP, Badmanaban R, Sen DJ, Patel CN. Synthesis and biological evaluation of 2,4,5-triphenyl-1H-imidazole-1-yl derivatives. *J Appl Pharm Sci*. 2012;2(7):202-208.
5. Yogita M, Kidrant B, Moon A. A review on synthesis of 2,4,5-triphenyl imidazole. *Int J Res Publ Rev*. 2024 Apr;8923-8926.
6. Zala SP, Badmanaban R, Sen DJ, Patel CN. Synthesis and biological evaluation of 2,4,5-triphenyl-1H-imidazole-1-yl derivatives. *J Appl Pharm Sci*. 2012 Jul 30;2(7):202-8.
7. Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz KA. Imidazoles as potential anticancer agents: An update on recent studies. *Molecules*. 2021;26(14):4213. doi:10.3390/molecules26144213.
8. Singh R, Jain DA. Development, characterization & stabilization of poorly water soluble drugs utilizing solid dispersion techniques by using β-cyclodextrin. *J Drug Deliv Ther*. 2013;3(2):74-79.
9. Zhang L, Peng XM, Damu GLV, Geng RX, Zhou CH. Comprehensive review in current developments of imidazole-based medicinal chemistry. *Med Res Rev*. 2014;34:–. doi:10.1002/med.21290.
10. Li SR, Tan YM, Zhang L, Zhou CH. Comprehensive insights into medicinal research on imidazole-based supramolecular complexes. *Pharmaceutics*. 2023;15:1348.
11. Kapoor R, Mittal P, Sharma A. Synthesis of novel Mannich bases of 2,4,5-triphenyl imidazole using pharmacologically active secondary amines. *Plant Arch*. 2020;20(1):476-8.
12. Abitha H, Anjana M, Gopika V, Jaseera Rahmath KA, Ranjana, Santhosh A. Design, synthesis and evaluation of novel triphenyl imidazole derivatives through in silico studies. *Int J Pharm Sci Rev Res*. 2025;85(4):182-5.
13. Yogita M, Kidrant B, Moon A. A review on synthesis of 2,4,5-triphenyl imidazole. *Int J Res Publ Rev*. 2024 Apr;8923-6.
14. Zala SP, Badmanaban R, Sen DJ, Patel CN. Synthesis and biological evaluation of 2,4,5-triphenyl-1H-imidazole-1-yl derivatives. *J Appl Pharm Sci*. 2012 Jul 30;2(7):202-8.
15. Scior T, Domeyer D, Cuanalo-Contreras K, Laufer S. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold. *Curr Med Chem*. 2011;18:1526-39. doi:10.2174/092986711795328409.
16. Al-Blewi F, Shaikh SA, Naqvi A, Aljohani F, Aouad MR, Ihmaid S, Rezki N. Design and synthesis of novel imidazole derivatives possessing triazole pharmacophore with potent anticancer activity, and in silico ADMET with GSK-3β molecular docking investigations. *Int J Mol Sci*. 2021;22(3):1162.
17. Nguyen TT, Le NPT. An efficient multicomponent synthesis of 2,4,5-trisubstituted and 1,2,4,5-tetrasubstituted imidazoles catalyzed by a magnetic nanoparticle-supported Lewis acidic deep eutectic solvent. *RSC Adv*. 2019; Electronic Supplementary Material.
18. Siwach A, Verma PK. Synthesis and therapeutic potential of imidazole-containing compounds. *BMC Chem*. 2021;15(1).
19. Lakshmidevi VR, Reeja D, Rajan AR, Vinod B. Advanced spectrum of imidazole derivatives in therapeutics: A review. *J Chem Rev*. 2023;5(3):241-62. doi:10.22034/jcr.2023.385802.1215.
20. Rajkamal B, Arun P, Shailendra P, Bhavesh P. Synthesis of some novel derivatives of 2,4,5-triphenyl imidazole through the novel method. *World J Pharm Res*. 2019;8(9):1350-7.
21. Scior T, Domeyer D, Cuanalo-Contreras K, Laufer S. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold. *Curr Med Chem*. 2011;18:1526-39. doi:10.2174/092986711795328409.
22. Mohamed SK, Simpson J, Marzouk AA, Talybov AH, Abdelhamid AA, Abdullayev YA, Abbasov VM. Multicomponent green synthesis, spectroscopic and structural investigation of multi-substituted imidazoles. Part 1. *Z Naturforsch B*. 2015;70(11):809-17.
23. Haghighijoo Z, Firuzi O, Meili S, Edraki N, Khoshneviszadeh M, Miri R. Design and synthesis of novel 1-hydroxy-2,4,5-triaryl imidazole derivatives as anti-cytokine agents. *Iran J Pharm Res*. 2020;19(1):181-91.
24. Ali I, Lone MN, Aboul-Enein HY. Imidazoles as potential anticancer agents. *MedChemComm*. 2017;8(9):1742–73.

25. Toufique Ahmed M, Shyamal Kumar B. Rational design and pharmacological profiling of triphenyl imidazole derivatives synthesized from 4-hydroxybenzaldehyde. *Int J Innov Res Technol*. 2019.
26. Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz KA. Imidazoles as potential anticancer agents: An update on recent studies. *Molecules*. 2021;26(14):4213.
27. Andrei GŞ, Andrei BF, Roxana PR. Imidazole derivatives and their antibacterial activity: A mini-review. *Mini Rev Med Chem*. 2021;21(11):1380–92.
28. Yasodha A, Sivakumar A, Arunachalam G, Puratchikody A. Synthesis and biological evaluation of some 2,4,5-triphenyl imidazole derivatives. *J Pharm Sci Res*. 2009;1(4):127–30.